Floatz logo

tno155

Kirsten Rat Sarcoma (KRAS) pG12C Mutation

AmgenPhase 1Active
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
95/ 100

Competitive context

19 Active assets in the Kirsten Rat Sarcoma (KRAS) pG12C Mutation cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Amgen
Phase 1CC
Atezolizumab
Amgen
Phase 1CC
Docetaxel
Amgen
Phase 1CC
Eloxatin
Amgen
Phase 1CC
Sotorasib
Amgen
Phase 1CC

View all 19 →

Same molecule, other indications

tno155 is also rated in:

KRAS G12C Mutant Solid TumorsDormant
CC
Indicative ·
45 / 100
View asset →
colorectal carcinomaDormant
CC
Indicative ·
45 / 100
View asset →
lung cancerDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →